DUBLIN–(BUSINESS WIRE)–The “Sedation
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
Sedation – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Sedation (Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
The Sedation (Central Nervous System) pipeline guide also reviews of key
players involved in therapeutic development for Sedation and features
dormant and discontinued projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III and Preclinical stages are 3 and 3 respectively. Similarly,
the Universities portfolio in Preclinical stages comprises 1 molecules,
Sedation (Central Nervous System) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic
landscape of Sedation (Central Nervous System).
The pipeline guide reviews pipeline therapeutics for Sedation (Central
Nervous System) by companies and universities/research institutes
based on information derived from company and industry-specific
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
The pipeline guide reviews key companies involved in Sedation (Central
Nervous System) therapeutics and enlists all their major and minor
The pipeline guide evaluates Sedation (Central Nervous System)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued
The pipeline guide reviews latest news related to pipeline
therapeutics for Sedation (Central Nervous System)
Reasons to Buy
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under
development for Sedation (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding
Sedation (Central Nervous System) pipeline depth and focus of
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
- Drawbridge Pharmaceuticals Pty. Ltd.
- Jiangsu Hengrui Medicine Co. Ltd.
- Jiangsu Nhwa Pharmaceutical Corp. Ltd.
- Paion AG
Featured News & Press Releases
Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with
Remimazolam in the U.S. As Sufficient; no Second Intranasal Study
Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented
at the Chest Annual Meeting 2017
Sep 28, 2017: European Patent Office Grants Formulation Patent For
Remimazolam In The EU
Jun 28, 2017: Paion reports positive headline data in U.S. Phase III
trial with Remimazolam for procedural sedation undergoing Bronchoscopy
Mar 28, 2017: Paion successfully completes patient recruitment in U.S.
Phase III study with Remimazolam for procedural sedation during
Mar 27, 2017: Paion reports positive headline data in U.S. Clinical
safety trial of Remimazolam in high-risk patients undergoing
Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results
Presented at the 2016 American College of Gastroenterology Annual
Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be
Presented at the American College of Gastroenterology 2016 Meeting
Sep 06, 2016: PAION announces clinical development progress with
remimazolam by its Partner Yichang Humanwell in China
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In
Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In
Phase III Study With Remimazolam For Procedural Sedation During
Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance
Patent For Remimazolam Besylate
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial
In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial
of Remimazolam in High Risk Patients Undergoing Colonoscopy
Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority
PMDA About Production Of Remimazolam For Japan
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fw7oxh
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900